RxDoctor Payments DataLook up a doctor →

Jason Rogers, MD

Cardiovascular Disease · Sacramento, CANPI 1295717163

Payments from drug & device makers

$5,062,660in general payments, 2019–2025

Across 695 payments — averaging $7284.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3.2M
  • Abbott$798K
  • Johnson & Johnson$716K
  • W. L. Gore & Associates, Inc.$170K
  • Biosense Webster, Inc.$149K
  • Edwards Lifesciences$17K
  • plus $17K from 13 others
$23,266in research payments, 2019–2025

Across 8 payments — averaging $2908.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$23K

What the payments were for

  • Consulting fees$575,34713%
  • Speaking & faculty fees$147,5673%
  • Grants$1950%
  • Travel & lodging$66,6772%
  • Food & beverage$22,7051%
  • Education$140%
  • Ownership interest$2,944,18467%
  • Other$618,89814%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,062,660 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$83,495
Medicare patients
235
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$109,859
JardianceEmpagliflozin19$23,234
XareltoRivaroxaban22$22,142
EntrestoSacubitril/Valsartan13$20,033
Repatha SureclickEvolocumab26$19,632
BrilintaTicagrelor24$13,616
Atorvastatin Calcium169$4,145
ClopidogrelClopidogrel Bisulfate63$3,012
Rosuvastatin Calcium41$2,099
Metoprolol Succinate103$2,016
Lisinopril121$1,259
Potassium Chloride25$736
Amlodipine Besylate86$726
Losartan Potassium41$649
Pravastatin Sodium26$570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$716,056$22,14222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →